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To the Editor: 
 
Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease 
characteristically affecting the elderly.1 The disease is due to an autoimmune 
response against hemidesmosomal antigens, involving autoreactive T and B cells. 
Interleukin (IL)-5 is abundantly expressed in lesional skin, and is associated with 
blood eosinophilia and eosinophil infiltration in the skin of BP patients.2,3 There is 
evidence that eosinophils, following activation with IL-5 in the presence of BP 
antibodies, may directly contribute to blister formation.4  
 
Superpotent topical and oral corticosteroids as well as doxycycline are 
currently used to treat BP patients.1 Nevertheless, use of steroids is limited by their 
side effects, and after discontinuation of therapy, BP relapses in 85% of patients 
within 6 months.5 Since eosinophils are characteristically found in the skin at early 
stages of the disease before blisters occur, targeting eosinophils by reducing their 
number and activation promised an alternative therapeutic approach. Anti-IL-5 
antibody (mepolizumab) therapy has been shown to be effective in eosinophilic 
bronchial asthma and hypereosinophilic syndrome.6-8  
 
The objective of the presented trial was to investigate the efficacy and safety 
of mepolizumab versus placebo as an add-on therapy to oral corticosteroids (OCS) 
in patients with an acute flare-up of BP. We conducted a randomized, placebo-
controlled, double-blind, parallel-group, phase 2 pilot study at a single academic 
center (NCT01705795). The trial was approved by the cantonal ethics committee 
Bern and the regulatory agency Swissmedic. All the participants provided written 
informed consent prior to enrollment in the study.  
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After screening, participants were randomly assigned in a 2:1 ratio to receive 
intravenous mepolizumab at a dose of 750 mg or matching placebo every 4 weeks 
over 12 weeks in addition to standard care with OCS, and followed over a period of 
up to 6 months after treatment. The OCS dose was 0.5 mg prednisolone per kg body 
weight until no further blisters and/or BP lesions appeared, and was then tapered by 
20% every 2 weeks. Enrolled patients presented with either a newly diagnosed 
disease or a relapse of BP.1 The primary endpoint was the cumulative rate of 
relapse-free patients after initiating therapy. Additional information on the study 
design (Figure S1, Tables S1 and S2) and the statistical analyses is provided in this 
article's online supporting information.  
 
In total, 32 patients were enrolled, and 30 underwent randomization and 
received at least one dose of the trial regimen and thus were included in the 
intention-to-treat population. The patients’ characteristics and diagnostic findings at 
baseline are given in Table S3 in this article's online supporting information. 
 
The proportion of patients free of BP relapse did not differ between 
mepolizumab and placebo groups as assessed 4 weeks after the end of treatment 
(week 16) and at the end of follow-up (week 36) (Table 1, Figure 1A).  Moreover, 
there were no significant differences in median time until relapse between groups. 
Thereby, the trial failed to achieve the primary endpoint. In addition, the cumulative 
rates of patients achieving disease control and maintaining disease control did not 
show significant differences between mepolizumab and placebo groups (Figure 1B-
C). Upon treatment, an overall improvement of BP clinical signs as indicated by a 
reduction of the severity score, and the intensity of pruritus were noted in both 
mepolizumab and placebo groups. Despite the fact that mepolizumab did not 
significantly affect the clinical outcome, we found significantly lower peripheral blood 
eosinophil levels in patients treated with mepolizumab compared to patients 
receiving placebo (Table 1). 
 
Next, we were interested whether mepolizumab would have an effect on skin 
inflammation (Table S4, Figure S2 in this article's online supporting information). In 
both groups, the mean number of skin infiltrating eosinophils was reduced upon 
therapy. The mean difference in eosinophil numbers was higher in the mepolizumab 
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compared with the placebo group (-62.8 versus -45.9; p=0.68). The number of cells 
expressing IL-5 did not decrease in either mepolizumab or placebo groups. 
Furthermore, we did not observe any significant differences in the numbers of T cell, 
mast cells, and cells expressing IL-13 or IFN-.  
 
The overall percentage of patients with adverse and serious adverse events 
was considerable, something which can be accounted for by the age of the patients 
and their various co-morbidities. Despite the relatively high number of serious 
adverse events, none of them was related to mepolizumab. The uncontrolled 
diabetes observed in one patient was most likely due to the OCS therapy. Five 
patients discontinued the study medication because of a lack of efficacy (Figure S1 
and Table S5 in this article's online supporting information).  
 
Based on the observation that eosinophils are present in BP lesions and are 
capable of splitting the skin at the dermal-epidermal junction in an ex vivo model,4 
we launched this investigator-initiated trial to study the effect of mepolizumab, an 
anti-IL-5 antibody, that might reduce the number and activity of eosinophils in 
patients with active BP. Unfortunately, we could not demonstrate any superiority of 
mepolizumab therapy over placebo in terms of the clinical and serological outcomes.  
 
What reasons might explain the failure of mepolizumab to significantly 
improve BP? 1. The total number of patients enrolled in this proof-of-concept study, 
was modest. It can be assumed that small effects of mepolizumab might have been 
detectable in a larger cohort and by calculating a higher study power. 2. Since we 
could not estimate the effect of mepolizumab in these elderly patients in advance, for 
ethical reasons, we chose an add-on therapy, i.e. mepolizumab or placebo were 
administered in addition to the standardized therapy with OCS. This design may 
have obscured possible effects of mepolizumab. 3. The treatment period with the 
study drug was limited to 12 weeks. This time-period may have been rather short to 
achieve long-term control of BP.  
 
 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
As expected, mepolizumab significantly decreased blood eosinophil numbers. 
However, it did not significantly affect tissue eosinophil infiltration. Even after 
therapy, eosinophils were detectable in the skin both in patients with and without 
relapse of BP. The observation that mepolizumab insufficiently controls tissue 
eosinophil numbers has been reported in other trials with bronchial asthma and 
eosinophilic esophagitis.7, 8  
 
Based on the experimental observations of a role for eosinophils in BP4, we 
would still argue for continuing investigation of therapeutic strategies targeting 
eosinophil activity and/or numbers. In this context, novel therapeutic antibodies 
against the IL-5 receptor alpha subunit would seem to be promising since they 
mediate antibody-dependent cell-mediated cytotoxicity of both eosinophils and 
basophils.9 Moreover, bertilimumab, an anti-eotaxin antibody, has recently been 
designated as an orphan drug for the treatment of BP by the Food and Drug 
Administration.  
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TABLE 1. Intention-to-treat analysis of efficacy 
 
Mepolizumab (N=20) Placebo (N=10) 
P* N 
events 
Cumulative 
survival rate 
(95% CI) 
N 
events 
Cumulative 
survival rate 
(95% CI) 
Cumulative relapse-free 
survival rates 
     
End of treatment (16 
weeks) 
6 
66.7% (44.9 - 
88.5) 
4 
55.6% (23.1 - 
88.1) 
0.74 
End of follow-up (36 
weeks) 
14 20.0% (0.6 - 39.4) 6 33.3% (2.5 - 64.1) 0.53 
Median survival time 
(weeks) 
20.0 (8.4 - 31.6) 24.6 (0.0 - 51.3)  
Cumulative rates of 
patients reaching  
disease control 
     
First 2 weeks 15 86.1% (69.0 - 100) 8 80.0% (55.3 - 100) 0.27 
End of treatment (16 
weeks) 
17 100% (nc) 10 100% (nc) 0.24 
Median time (weeks) 1.14 (1.03 - 1.26) 1.71 (1.42 - 2.00)  
Cumulative rates of 
patient maintaining 
disease control** 
     
End of treatment (16 
weeks) 
5 
68.6% (45.7 - 
91.5) 
4 
50.0% (15.3 - 
84.7) 
0.48 
End of follow-up (36 
weeks) 
13 21.2% (0.8 - 41.6) 6 33.3% (2.5 - 64.1) 0.73 
Median time (weeks) 19.0 (10.7 - 27.3) 16.0 (8.1 - 23.9)  
ABSI score reduction 
from baseline 
Mean (95% CI)*** Mean (95% CI)***  
Average in the first 16 
weeks 
25.6 (18.1 - 33.2) 21.6 (11.1 - 32.2) 0.52 
Average in the overall 
study period (36 weeks) 
28.1 (20.3 - 35.9) 32.8 (14.8 - 50.8) 0.43 
Pruritus NRS reduction 
from baseline 
Mean (95% CI)*** Mean (95% CI)***  
Average in the first 16 
weeks 
4.5 (3.4 - 5.5) 4.4 (2.9 - 5.8) 0.90 
Average in the overall 
study period (36 weeks) 
4.3 (3.2 - 5.4) 4.8 (3.3 - 6.3) 0.62 
Cumulative dose of 
systemic corticosteroids 
until clinical remission 
Mean (95% CI) Mean (95% CI)  
257.5 (185.3 - 329.7) 445.0 (167.5 - 722.5) 0.16**** 
Peripheral blood 
eosinophils 
Mean (95% CI) ***** Mean (95% CI) *****  
Average in the first 16 
weeks 
0.04 (0.00 - 0.09) 0.16 (0.09 - 0.22) 0.007 
Average in the overall 
study period (36 weeks) 
0.05 (0.01 - 0.10) 0.26 (0.20 - 0.33) <0.001 
ELISA BP 180 AB Mean (95% CI) ***** Mean (95% CI) *****  
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(RU/ml) 
Average in the first 16 
weeks 
10.0 (-12.9 - 33.1) 6.6 (-21.6 - 34.8) 0.66 
Average in the overall 
study period (36 weeks) 
14.9 (-3.3 - 33.1) 7.5 (-20.5 - 35.5) 0.65 
ELISA BP 230 AB  
(RU/ml) 
Mean (95% CI) ***** Mean (95% CI) *****  
Average in the first 16 
weeks 
3.9 (-1.6 - 9.4) -0.3 (-7.2 - 6.7) 0.52 
Average in the overall 
study period (36 weeks) 
4.5 (0.2 - 8.7) -0.7 (-7.7 - 6.3) 0.52 
ABSI: autoimmune bullous skin disorder intensity, CI: confidence interval, NRS: numerical rating 
scale, ELISA: enzyme-linked immunosorbent assay,  BP180 AB, BP230 AB: antibodies to bullous 
pemphigoid hemidesmosomal antigens BP180 and BP230, RU: relative units. 
 
* Log-rank test 
** Comparisons were performed on patients who had achieved disease control (17 in the 
mepolizumab and 10 in the placebo groups) 
*** Estimated marginal means from mixed linear regression models 
**** Mann-Whitney U test 
***** Estimated marginal means from mixed linear regression models including baseline levels of each 
parameter as adjustment factors 
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Figure legend 
 
FIGURE 1  Rates of BP patients free of relapse, achieving disease control, and 
maintaining disease control. The Kaplan-Meier curves show (A) the cumulative 
relapse-free survival, (B) the cumulative disease-control rate, and (C) the disease-
control maintenance rate in the mepolizumab (solid line) and placebo groups 
(dashed line). 
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